# Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

> **NCT00493766** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Hormone Refractory Prostate Cancer

## Interventions

- **DRUG:** LBH589

## Key facts

- **NCT ID:** NCT00493766
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2008-07
- **Final completion:** —
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Because of a strategic decision by Novartis
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00493766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00493766, "Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00493766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*